In the 2020 Yanwei Machinery Company’s annual meeting, Mr. Jiang is giv...

Group photo of all employees of the company in 2015

Sarah earned her BA from Harvard College in East Asian Studies and her JD from Harvard Law School. He worked previously at Global Prior Art, an intellectual property analysis firm, as a Partner and the Director of the Life Sciences Division. She holds a BA in Public Administration with a minor in International Affairs from Texas State University. Peter Kolchinsky, Ph.D. Prior to joining RA, Emily was Chief Business Officer of Prevail Therapeutics from the companys inception in 2017 until its acquisition by Eli Lilly in 2021. Joshs primary responsibility at RA Capital is to lead early-stage private investments in and oversee the creation of new companies developing drugs, medical devices, diagnostics, and research tools. Peter Kolchinsky - RA Capital Management - Insider Monkey Brigid holds a BS in Chemistry (Hons) from the Commonwealth Honors College at the University of Massachusetts, Amherst (2002) and a PhD in Materials Science and Engineering from Johns Hopkins University (2009). Before her time at New Care, she was a Student Researcher at Boston Childrens Hospital Labs of Cognitive Neuroscience. Tim was responsible for building the commercial team at GelTex and launching Renagel, a novel treatment for patients with kidney failure that grew to a $1B franchise . Garrett has worked cross-functionally across the landscape of in vivo and ex vivo genetic medicine modalities, often at the interface of payload design, platform research and manufacturing, IND-enabling activities, bioanalytical and computational biology, and strategy. Matthew works on both public and private investments and serves as a Board Director for Cerebral Therapeutics, DTx Pharma, Emergence Therapeutics, Forge Biologics, Jnana Therapeutics, and Kira Pharmaceuticals. Alonso completed his Ph.D. in Chemistry at the University of Florida and his post-doctoral work as a Howard Hughes Medical Institute Fellow at Harvard University and the Massachusetts General Hospital. and Ultragenyx Pharmaceuticals. Anurag works on both public and private investments with a focus on Healthcare, Technology, and Services. Katherine Terranova is an Associate within the TechAtlas division of RA Capital Management. Kathryn has a BS in Exercise and Health Science from the University of Massachusetts Boston. Erich holds a BA in English Literature and Language from Harvard University and a PhD in Microbiology from the University of North Carolina, Chapel Hill. During his time at Flagship, Tom also served as Co-Founder, Head of Translational Biology at a stealth ProtoCo. Zach holds a BS in Molecular Biophysics and Biochemistry from Yale University, and a PhD in Neurobiology and Behavior from the University of Washington. Cosmas Giallourakis is a Venture Partner at RA Ventures, focusing on new company creation. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Emory has a BS from Vassar College and an MD from the Harvard-MIT Health, Science, Technology Program at Harvard Medical School. Age 46 / Jul 1976. Mario has more than two decades of experience in vaccinology, virology and immunology in large pharma, government, academy, and biotech settings. Senior Research Assistant, Venture Analytics. Astha is a Senior Data Analyst Associate at RA Capital Management. Sadik and his teams have contributed to the successful BLA and MAA applications for three of the commercially available CAR-T therapies: Kymriah, Yescarta, and Tecartus. Megans primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Habib has earned his Director Professionalism Certificate from the National Association of Corporate Directors. He was Chief Medical Officer of Ra Pharmaceuticals from 2016 until it was acquired by UCB in 2020. Soumya obtained his PhD in X-ray Crystallography and Biophysics from the Indian Institute of Science while working as visiting research scholar at Rockefeller University. David Migl is an Analyst on the Investment Team at RA Capital Management. Cristina has nearly a decade of experience in the biotech and life sciences industries. Prior to joining RA, Michael was Associate Vice President at Merck Research Labs. Prior to Point32Health, Michael served as CMO of Harvard Pilgrim Health Care, the Corporate Medical Director at Humana and also served as Vice President of Network and Consumer Solutions for UnitedHealth Groups subsidiary Ingenix (now part of Optum). The Great American Drug Deal | Peter Kolchinsky, PhD - NetGalley Prior to RA, Drew gained experience in Data Science in Technical Consultant roles at ExxonMobil. His laboratory at the Broad focused on advanced high throughput biotechnology tools including DNA synthesis, single cell analysis, synthetic biology derived biomolecule libraries, and microbiome profiling. Peter Pan & Wendy review - Jude Law has fun in a so-so reinvention Michael conducts due diligence on biotechnology companies at RA Capital. Previously, Laura covered hematologic malignancies, cell therapies, retinal diseases, and orphan neurodevelopmental disorders. Peter Kolchinsky founded 5 companies, among them: Research Alliance Corp. II, Therapeutics Acquisition Corp. and RA Capital Management LP (Private Equity). Tammeil Gilkerson Husband, What Happened To David Hodges And Ashley Terkeurst, Articles P